CAR T cell therapy has transformed the treatment of B cell cancers and is now being pursued by biotech companies for conditions as varied as systemic lupus erythematosus, diabetes and organ rejection.
This is a preview of subscription content, log in via an institution to check access.
References
Kansal, R. et al. Sci. Transl. Med. 11, eaav1648 (2019).
Mougiakakos, D. et al. New Engl. J. Med. 385, 567–569 (2021).
Mackensen, A. et al. Nat. Med. 28, 2124–2132 (2022).
Klatzmann, D. et al. Science 225, 59–63 (1984).
Harrison, A. J., Du, X., von Scheidt, B., Kershaw, M. H. & Slaney, C. L. Immunother. Adv. 1, ltab016 (2021).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Arnold, C. Autoimmune disease is the next frontier for CAR T cell therapy. Nat Med 30, 6–9 (2024). https://doi.org/10.1038/s41591-023-02716-7
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41591-023-02716-7
- Springer Nature America, Inc.
This article is cited by
-
Deciphering the importance of culture pH on CD22 CAR T-cells characteristics
Journal of Translational Medicine (2024)